se of Anti glaucoma eyedrop Ripasudil for treatment of corneal edema caused by cataract surgery
Not Applicable
- Conditions
- Health Condition 1: - Health Condition 2: H181- Bullous keratopathyHealth Condition 3: H00-H59- Diseases of the eye and adnexa
- Registration Number
- CTRI/2022/03/041064
- Lead Sponsor
- Office of Director General Armed Forces Medical Services
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients who develop immediate corneal edema, that is, corneal edema observed on day one after undergoing cataract surgery would be initially enrolled in the study.
Exclusion Criteria
Pre-operative factors
Eyes with advanced retinal pathology, corneal pathology such as dystrophies, degenerations or prior corneal trauma with residual scarring
Chronic diagnosed glaucoma or ocular hypertension at baseline examination
Use of any topical medication that is toxic to corneal endothelium
Diabetes mellitus
Immunocompromised states
Postoperative complications
Endophthalmitis, toxic anterior segment syndrome, postoperative rise in IOP (to >21mm Hg)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To study and compare the effect of Rho kinase inhibitor Ripasudil with standard treatment versus standard treatment alone on Central Corneal Thickness(CCT) after 4 weeks, in patients with corneal edema following cataract surgery.Timepoint: Baseline, 1 week, 2 weeks, 4 weeks
- Secondary Outcome Measures
Name Time Method 1.To evaluate and compare change in Endothelial Cell Density (ECD) after 4 weeks in the two groups.Timepoint: Baseline, 1 week, 2 weeks, 4 weeks